The dalfopristin or dalfopristin intermediate product having purity higher than 99% can be obtained by performing separation and purification for once, and the yield is high.
Specifically, the present invention relates to a separation and purification method for dalfopristin and an intermediate thereof.
certain antibiotics - such as quinupristin/dalfopristin, rifabutin, fusidic acid
Co-administration of quinupristin / dalfopristin and nifedipine may lead to increased plasma concentrations of nifedipine.
Co-administration of quinupristin / dalfopristin and nifedipine may lead to increased plasma concentrations of nifedipine.
Quinupristin and dalfopristin are the main active components circulating in plasma in human subjects.
Only a few cases were found to be resistant to linezolid and quinupristin/dalfopristin between 2009 and 2014.
The elimination half-life of quinupristin and dalfopristin is approximately 0.85 and 0.70 hours, respectively.
Simultaneous administration of quinupristin / dalfopristin and nifedipine, may lead to increased plasma concentrations of nifedipine (see Section 4.4).
The invention concerns combinations having synergy of action characterised in that they consist of a combination of quinupristine/dalfopristine with cefpirome, and compositions and presentation kits comprising same.
VRE may be treated with quinupristin/dalfopristin (Synercid) with response rates of approximately 70%.
VRE may be treated with quinupristin/dalfopristin (Synercid) with response rates around 70%.
Simultaneous administration of quinupristin / dalfopristin and nifedipine may lead to increased plasma concentrations of nifedipine (see section 4.4).
The method of the present invention is economical and highly-efficient, and achieves ideal selectivity and purification effects on isomer impurities in the crude product of dalfopristin or dalfopristin intermediate.
Simultaneous administration of cisapride and nifedipine or quinupristin/dalfopristin and nifedipine may lead to increased plasma concentration of nifedipine.
In patients undergoing Continuous Ambulatory Peritoneal Dialysis, dialysis clearance for quinupristin, dalfopristin and their metabolites is negligible.
Out of the 368 cases tested for resistance, one was determined to be resistant to linezolid and ten were resistant to quinupristin/dalfopristin.
The penetration into blister fluid of quinupristin and dalfopristin in combination with their major metabolites was in total approximately 40% compared to that in plasma.
The same applies to the combination of fosfomycin with most anti-staphylococcal (linezolid, quinupristin/dalfopristin, moxifloxacin) agents in the treatment of staphylococcal infections.
Based on experience with the calcium-antagonist nifedipine, co-administration of quinupristin/dalfopristin may lead to increased plasma concentrations of nimodipine (see section 4.4).
Penetration of unchanged quinupristin and dalfopristin in noninflammatory blister fluid corresponds to about 19% and 11% of that estimated in plasma, respectively.
Requêtes fréquentes français :1-200, -1k, -2k, -3k, -4k, -5k, -7k, -10k, -20k, -40k, -100k, -200k, -500k, -1000k,
Requêtes fréquentes anglais :1-200, -1k, -2k, -3k, -4k, -5k, -7k, -10k, -20k, -40k, -100k, -200k, -500k, -1000k,
Traduction Translation Traducción Übersetzung Tradução Traduzione Traducere Vertaling Tłumaczenie Mετάφραση Oversættelse Översättning Käännös Aistriúchán Traduzzjoni Prevajanje Vertimas Tõlge Preklad Fordítás Tulkojumi Превод Překlad Prijevod 翻訳 번역 翻译 Перевод